Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Concord Biotech Ltd (CONB)
Concord Biotech Ltd stock price live, this page displays NSE CONB stock exchange data. View the CONB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Concord Biotech Ltd real time stock price chart below.
What Is the Concord Biotech Ltd Stock Price Today?
The Concord Biotech Ltd stock price today is 1,018.40.
What Is the Stock Symbol for Concord Biotech Ltd?
The stock symbol for Concord Biotech Ltd is "CONB."
What Stock Exchange Does Concord Biotech Ltd Trade On?
Concord Biotech Ltd is listed and trades on the NSE stock exchange.
Is Concord Biotech Ltd a Good Stock to Buy?
Determining whether Concord Biotech Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CONB quote. (ISIN: INE338H01029)
What Is the Concord Biotech Ltd Stock Price Today?
The Concord Biotech Ltd stock price today is 1,018.40.
What Is the Stock Symbol for Concord Biotech Ltd?
The stock symbol for Concord Biotech Ltd is "CONB."
What Stock Exchange Does Concord Biotech Ltd Trade On?
Concord Biotech Ltd is listed and trades on the NSE stock exchange.
Is Concord Biotech Ltd a Good Stock to Buy?
Determining whether Concord Biotech Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CONB quote. (ISIN: INE338H01029)
1,018.40
+3.60(+0.35%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
990.60
1,036.80
52 wk Range
990.60
2,150.40
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
990.601,036.80
52 wk Range
990.602,150.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.03%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.03%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
CONB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
1,426.67
Upside
+40.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
- Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Concord Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Compare CONB to Peers and Sector
Metrics to compare | CONB | Peers Peers - average of corresponding metrics from companies closely matching CONB: ALKEM, SUNPHARMA, LUPIN, GLAND, NEULANDLAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCONBPeersSector |
|---|---|---|---|---|
P/E Ratio | 34.1x | 26.5x | −0.4x | |
PEG Ratio | −7.09 | 0.37 | 0.00 | |
Price/Book | 5.8x | 3.9x | 2.6x | |
Price / LTM Sales | 9.2x | 3.5x | 3.1x | |
Upside (Analyst Target) | 39.9% | 11.6% | 58.2% | |
Fair Value Upside | Unlock | 6.7% | 8.5% | Unlock |
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1,426.67
(+40.09% Upside)
Earnings
Latest Release
Feb 11, 2026
EPS / Forecast
6.30 / --
Revenue / Forecast
2.78B / --
People Also Watch
FAQ
What Is the Concord Biotech (CONB) Stock Price Today?
The Concord Biotech stock price today is 1,018.40 INR.
What Stock Exchange Does Concord Biotech Trade On?
Concord Biotech is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Concord Biotech?
The stock symbol for Concord Biotech is "CONB."
Does Concord Biotech Pay Dividends? What’s The Current Dividend Yield?
The Concord Biotech dividend yield is 1.03%.
What Is the Concord Biotech Market Cap?
As of today, Concord Biotech market cap is 106.16B INR.
What Is Concord Biotech's Earnings Per Share (TTM)?
The Concord Biotech EPS (TTM) is 29.69.
When Is the Next Concord Biotech Earnings Date?
Concord Biotech will release its next earnings report on May 21, 2026.
From a Technical Analysis Perspective, Is CONB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Concord Biotech Stock Split?
Concord Biotech has split 0 times.
How Many Employees Does Concord Biotech Have?
Concord Biotech has 1571 employees.
What is the current trading status of Concord Biotech (CONB)?
As of Mar 30, 2026, Concord Biotech (CONB) is trading at a price of 1,018.40 INR, with a previous close of 1,014.80 INR. The stock has fluctuated within a day range of 990.60 INR to 1,036.80 INR, while its 52-week range spans from 990.60 INR to 2,150.40 INR.
What Is Concord Biotech (CONB) Price Target According to Analysts?
The average 12-month price target for Concord Biotech is 1,426.67 INR, with a high estimate of 1680 INR and a low estimate of 1170 INR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.09% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.